Acelyrin Balance Sheet Health

Financial Health criteria checks 6/6

Acelyrin has a total shareholder equity of $568.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $651.7M and $83.5M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$635.24m
EquityUS$568.22m
Total liabilitiesUS$83.52m
Total assetsUS$651.74m

Recent financial health updates

Recent updates

Companies Like Acelyrin (NASDAQ:SLRN) Are In A Position To Invest In Growth

Aug 03
Companies Like Acelyrin (NASDAQ:SLRN) Are In A Position To Invest In Growth

Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis

Mar 13

Financial Position Analysis

Short Term Liabilities: SLRN's short term assets ($648.3M) exceed its short term liabilities ($82.5M).

Long Term Liabilities: SLRN's short term assets ($648.3M) exceed its long term liabilities ($1.1M).


Debt to Equity History and Analysis

Debt Level: SLRN is debt free.

Reducing Debt: SLRN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLRN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SLRN has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 65.7% each year.


Discover healthy companies